Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



Immune Cells and Immune Factors from Healthy Donors or Transplant Recipients

Not Available
N/A
Engelhardt, Brian
VICCBMT1645

High Dose Flu Vaccine in Treating Children Who Have Undergone Donor Stem Cell Transplant

This phase II randomized trial studies how well high dose flu vaccine works in treating children who have undergone done stem cell transplant. Higher dose flu vaccine may build a better immune response and may provide better protection against the flu than the standard vaccine.
Not Available
II
Halasa, Natasha
NCT02860039
VICCPED1647

Natalizumab and Prednisone or Methylprednisolone in Treating Participants with High Risk Acute Graft-Versus-Host Disease

This phase II trial studies how well natalizumab and prednisone or methylprednisolone work in treating participants with high risk acute graft-versus-host disease. Graft-versus-host disease is caused when cells from a donated stem cell graft attack the normal tissue of the transplant patient. Immunotherapy with monoclonal antibodies, such as natalizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Prednisone and methylprednisolone are steroids that helps suppress the immune system and reduce inflammation. It is not yet known how well natalizumab and prednisone or methylprednisolone work in treating participants with high risk acute graft-versus-host disease.
Not Available
II
Kitko, Carrie
NCT02133924
VICCPED1666

Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients

The purpose of this study is to compare the efficacy and safety of eflornithine in combination with lomustine, compared to lomustine taken alone, in treating patients whose anaplastic astrocytoma has recurred / progressed after radiation and temozolomide chemotherapy.
Not Available
III
Moots, Paul
NCT02796261
VICCNEU1670

Combination Chemotherapy with or without Temsirolimus in Treating Patients with Intermediate Risk Rhabdomyosarcoma

This randomized phase III trial studies how well combination chemotherapy (vincristine sulfate, dactinomycin, cyclophosphamide alternated with vincristine sulfate and irinotecan hydrochloride or vinorelbine) works compared to combination chemotherapy plus temsirolimus in treating patients with rhabdomyosarcoma (cancer that forms in the soft tissues, such as muscle), and has an intermediate chance of coming back after treatment (intermediate risk). Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Combination chemotherapy and temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether combination chemotherapy or combination chemotherapy plus temsirolimus is more effective in treating patients with intermediate-risk rhabdomyosarcoma.
Not Available
III
Borinstein, Scott
NCT02567435
COGARST1431

Cisplatin, Romidepsin and Nivolumab in Treating Patients with Locally Recurrent or Metastatic Triple Negative Breast Cancer

Breast

This phase I / II trial studies the side effects and best dose of romidepsin when given together with cisplatin and nivolumab, to see how well they work in treating patients with triple negative breast cancer that has come back at or near the same place as the original (primary) tumor, usually after a period of time during which the cancer could not be detected or spread to other parts of the body. Romidepsin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Romidepsin may also help cisplatin work better. Monoclonal antibodies, such as nivolumab, may interfere with the ability of tumor cells to grow and spread. Giving romidepsin together with cisplatin and nivolumab may be a better treatment for tripe negative breast cancer.
Breast
I/II
Abramson, Vandana
NCT02393794
VICCBRE1674

MRI-Ultrasound Fusion Targeted Prostate Biopsies - Quality Control & Performance Improvement

Prostate

Prostate
N/A
Resnick, Matthew
VICCURO1680

Tepotinib Phase II in Non-small Cell Lung Cancer (NSCLC) Harboring MET Alterations

Lung

This study will look at how effective the study drug (tepotinib) is at stopping the growth and spread of lung cancer. This study will also measure a number of other things including safety of the study drug and the side effects, how body processes the study drug, or how the study drug affects your quality of life. The study also has an optional pharmacogenetic research part. Pharmacogenetic research is an important way to try to understand the role of genetics in human disease and how genes impact the effectiveness of drugs, because differences in genes can change the way a person responds to a particular drug.
Lung
II
Horn, Leora
NCT02864992
VICCTHO1691

AACR Project GENIE: Breast Cancer Sub-Project

Not Available
N/A
Park, Ben
VICCBRE1694

My Pathway: A Study Evaluating Herceptin / Perjeta, Tarceva, Zelboraf / Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors

Miscellaneous

This multicenter, non-randomized, open-label study will evaluate the efficacy and safety of six treatment regimens in participants with advanced solid tumors for whom therapies that will convey clinical benefit are not available and / or are not suitable options per the treating physician's judgment.
Miscellaneous
II
Davis, Elizabeth
NCT02091141
VICCMD16103

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: